Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremie Calais

Showing results (71-80 of 207) with videos related to

Pageof 21
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 15, 2019
Radiation Dosimetry and Biodistribution of <sup>68</sup>Ga-FAPI-46 PET Imaging in Cancer PatientsCatherine Meyer, Magnus Dahlbom, Thomas Lindner, et al.
Cancer Treatment Reviews|March 18, 2023
Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancerJeremie Calais, Stephen M Eulau, Linda Gardner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 3, 2024
Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical TherapyJeremie Calais, Michael J Morris, Ayse Tuba Kendi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 12, 2020
<sup>68</sup>Ga-FAPi-46 diffuse bilateral breast uptake in a patient with cervical cancer after hormonal stimulationIda Sonni, Stephanie Lee-Felker, Sanaz Memarzadeh, et al.
EJNMMI Research|December 4, 2019
Evaluation of SUV normalized by lean body mass (SUL) in <sup>68</sup>Ga-PSMA11 PET/CT: a bi-centric analysisAndrei Gafita, Jeremie Calais, Charlott Franz, et al.
Clinical Nuclear Medicine|July 24, 2020
Incidental Detection of Elastofibroma Dorsi With 68Ga-FAPI-46 and 18F-FDG PET/CT in a Patient With Esophageal CancerArtineh Hayrapetian, Mark D Girgis, Jane Yanagawa, et al.
Seminars in Nuclear Medicine|April 22, 2026
The Role of FAPI PET/CT in the Assessment of Inflammatory DiseasesElnaz Jenabi, Masatoshi Hotta, Armin Atzinger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 21, 2021
High <sup>68</sup> Ga-FAPI-46 uptake in a pulmonary necrotizing granuloma in a patient with subcutaneous lipomaMasatoshi Hotta, Matthias R Benz, Martin S Allen-Auerbach, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2023
Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with <sup>177</sup>Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center AnalysisVishnu Murthy, Andrei Gafita, Pan Thin, et al.
The Lancet. Oncology|November 2, 2019
What is the best PET target for early biochemical recurrence of prostate cancer?-Authors' replyJeremie Calais, Francesco Ceci, Matthias Eiber, et al.
Pageof 21

Showing results (71-80 of 207) with videos related to

Sort By:
Pageof 21
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 15, 2019
Radiation Dosimetry and Biodistribution of <sup>68</sup>Ga-FAPI-46 PET Imaging in Cancer PatientsCatherine Meyer, Magnus Dahlbom, Thomas Lindner, et al.
Cancer Treatment Reviews|March 18, 2023
Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancerJeremie Calais, Stephen M Eulau, Linda Gardner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 3, 2024
Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical TherapyJeremie Calais, Michael J Morris, Ayse Tuba Kendi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 12, 2020
<sup>68</sup>Ga-FAPi-46 diffuse bilateral breast uptake in a patient with cervical cancer after hormonal stimulationIda Sonni, Stephanie Lee-Felker, Sanaz Memarzadeh, et al.
EJNMMI Research|December 4, 2019
Evaluation of SUV normalized by lean body mass (SUL) in <sup>68</sup>Ga-PSMA11 PET/CT: a bi-centric analysisAndrei Gafita, Jeremie Calais, Charlott Franz, et al.
Clinical Nuclear Medicine|July 24, 2020
Incidental Detection of Elastofibroma Dorsi With 68Ga-FAPI-46 and 18F-FDG PET/CT in a Patient With Esophageal CancerArtineh Hayrapetian, Mark D Girgis, Jane Yanagawa, et al.
Seminars in Nuclear Medicine|April 22, 2026
The Role of FAPI PET/CT in the Assessment of Inflammatory DiseasesElnaz Jenabi, Masatoshi Hotta, Armin Atzinger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 21, 2021
High <sup>68</sup> Ga-FAPI-46 uptake in a pulmonary necrotizing granuloma in a patient with subcutaneous lipomaMasatoshi Hotta, Matthias R Benz, Martin S Allen-Auerbach, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2023
Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with <sup>177</sup>Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center AnalysisVishnu Murthy, Andrei Gafita, Pan Thin, et al.
The Lancet. Oncology|November 2, 2019
What is the best PET target for early biochemical recurrence of prostate cancer?-Authors' replyJeremie Calais, Francesco Ceci, Matthias Eiber, et al.
Pageof 21